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Recurrent respiratory infections: A common occurrence in young children is of recurrent respiratory infections (RRIs). During the first 5 years of life, a child could 
develop 4–8 episodes of respiratory infections, which mainly 
affects the lower respiratory tract. There is no universal definition 
of RRIs and there are a lot of discrepancies about the same. 
Recurrence of three or more episodes of acute infections in a 
previous 6-month period suggests RRIs [1,2]. The most widely 
accepted definition is the occurrence of eight or more documented 
airway infections per year in pre-school-aged children (up to 
3 years of age) or of 6 or more in children older than 3 years of 
age, in the absence of any underlying pathological condition [3]. 
As per one recently published Indian consensus statement, RRI 
should be considered in patients with three or more episodes 
of respiratory infection or more than 15 days of respiratory 
symptoms in the past 3 months [4].
Recurrent infections of the respiratory airways lead to 
significant morbidity and mortality among pediatric patients. 
Furthermore, RRIs in children warrant repeated visits to 
pediatric clinics and hospital admissions. Another important 
consequence of pediatric RRIs is the rampant and irrational 
use of antibiotics. Most of the respiratory infections are viral in 
origin and frequent irrational use of broad-spectrum antibiotics 
can lead to antibacterial resistance. Despite the use of antibiotics 
and vaccines, the incidence of RRIs is still high in children 
due to the deficiency of the immune system [5]. The use of 
immunostimulants can help to reduce RRIs and ultimately can 
result in better clinical outcomes [5]. There is a good amount 
of clinical evidence about the role of immunostimulants as an 
adjuvant in the prevention and treatment of respiratory diseases 
in children [6]. Pidotimod (PDT), an immunostimulant molecule 
has been studied extensively in RRIs.
METHODOLOGY
The literature search was performed using PubMed and Google 
Scholar databases, and search terms used were pidotimod, 
children, and RRIs. In additional, the Google search engine was 
used to identify any other studies of PDT in children. Clinical 
studies of PDT in the English language were included in this 
review. In this review, 18 studies in children were included in the 
study. Different indications studied in these studies were RRIs 
(n=16 studies) and pneumonia (n=2 studies).
Burden of RRIs
Acute respiratory infections (ARIs) are the most common cause of 
morbidity and mortality worldwide [7,8]. Approximately 1.3 million 
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children under 5 years die per year from ARIs worldwide [9]. In 
low-income countries, one-third of the deaths in <5 years of age, 
are due to ARIs [10]. According to the World Health Organization 
estimates, respiratory infections account for 6% of the total global 
burden of disease. Each year ARIs account for over 12 million 
hospital admissions in children <5 years worldwide [11]. In the 
year 2016, lower respiratory infections caused 652,572 deaths in 
children younger than 5 years worldwide [12].
In developing countries, every child has 5 episodes of ARI/
year on an average, accounting for 30–50% of the total pediatric 
outpatient visits, and 20–30% of the pediatric admissions [13]. 
RTIs are a leading cause of childhood mortality, resulting in over 
2 million deaths per year in developing countries [3]. Recent 
community-based estimates from the prospective study report that 
70% of the childhood morbidities among children aged <5 years 
are due to ARI [13,14]. In India, ARIs are the most common cause 
of death among children <5 years [13].
Immune Dysfunction in Children with Recurrent Respiratory 
Tract Infections (RRTIs)
In children, immaturity in immune response involving activities 
of immune cells such as neutrophils, macrophage, dendritic cells 
(DCs), natural killer (NK) cells, B-cells, and T-cells has been 
observed and this contributes to RRIs in children [15].
The most common cause of RRIs in children are not 
severe immunodeficiency disorders, but low levels of immune 
parameters such as [4]: Defective phagocytosis and chemotaxis of 
macrophages and neutrophils, decreased toll-like receptor (TLR) 
function and ciliary function, and immaturity of DCs; decrease in 
immunoglobulins (Igs), namely, IgA, IgM, and IgG subclasses, 
decrease in the number of CD4+, CD8+, CD19+, and NK-cells, 
and alterations in the cytokine production by lymphocytes; 
and increased interleukin (IL) such as IL-4, IL-10, decreased 
interferon-gamma (IFN-γ), IL-12, and IL-2, and decreased 
Th1/Th2 ratio. According to a recent study in immunology, a 
functional disorder of Th1/Th2 cells or an immune hypofunction 
could result in the development of RRI in children [16].
Due to this immaturity of the immune system or reduced 
functioning of the immune cells, children including infants, 
pre-school children (3–5 years), and school-going children 
(5–14 years of age) are at risk of RRIs. Various studies from 
India also demonstrated that children <5 years of age suffer from 
RRI episodes up to 7–8/year until their immunity status reaches 
adult levels after 5 years of age. Even in school-going children, 
frequent RRIs were reported [4].
Risk Factors, Consequences, and Management of RRIs
In children, RRIs can be due to several risk factors like increased 
exposure to respiratory infectious agents during the first few years 
of life. This is very common, especially when the child is attending 
pre-school or school facilities, general immaturity of the immune 
system of children, environmental, and social factors, e.g., daycare 
attendance, family size, air pollution, and parental smoking [3].
RRIs in children can lead to the number of consequences such 
as frequent visits to pediatric clinics, school absenteeism, overuse 
of antibiotics and bacterial resistance, decreased quality of life, 
and economic burden on the family [3].
The children with RRIs represent a challenge to the pediatrician, 
both from the treatment as well as preventive aspect. Recurrence 
of respiratory infections can be attributed to host factors and 
environmental factors. Host factors may be immunological or 
non-immunological. Decreased immune function of the host is an 
important underlying factor for RRIs. Conventionally, the treatment 
of RRIs involves the use of antihistamines, antipyretics, and 
antibiotics. Recently, its prevention has gained focus as the overuse 
of antibiotics leads to antibiotic resistance and ineffectiveness of 
these medicines [17]. Drugs modulating the immune pathways are 
one of the new approaches in the management of RRIs in children. 
Immunostimulants which can stimulate both innate and adaptive 
immune system can be a very valuable therapeutic and preventive 
option in children with RRIs [3].
Pidotimod
It is a synthetic dipeptide molecule with immunostimulant 
properties. It acts on both innate and adaptive immunity [16]. It 
is indicated for treatment and prophylaxis of infections associated 
with immune deficiency [18].
Mechanism of Action
PDT induces the maturation of DC. These stimulated DCs further 
release pro-inflammatory molecules which drive T-cells proliferation 
and differentiation toward a Th1 phenotype [19]. Th1cells increase 
the activity of NK cells and promote phagocytosis. PDT directly 
increases levels of Th1-related cytokines and suppresses Th2 
cytokines in children with frequent infections [18]. PDT also elicits 
adaptive immune responses by restoring the proliferative response 
of T lymphocytes, secretion of Th1 cytokines, and by protecting 
thymocytes from apoptosis. PDT upregulates the expression of 
TLR-2. These TLR-2s are present on airway epithelial cells. It can 
modulate the inflammatory cascade triggered by TLR ligands [16].
PDT improves the immunological response to inflammatory 
stimuli acting on different immunological pathways. There is 
evidence for its ability to prevent experimental viral and bacterial 
infections. PDT has been shown to affect cell-mediated immune 
responses [18].
Pharmacokinetics
PDT has an oral bioavailability of 43–45%. Tmax is 1.5 h (range 
1.3–1.8 h). The rate and extent of absorption of pidotimod are 
reduced significantly when given with food. Oral bioavailability 
is decreased up to 50% after administration with food, and peak 
serum levels occur up to 2 h later, compared to administration 
in the fasting state [18]. To optimize absorption, PDT should be 
given 2 h before or after meals. It has a low protein binding of 4% 
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with a volume of distribution of 30 L. It shows minimal hepatic 
metabolism. Approximately 45% of an oral dose (200–800 mg) 
of PDT is excreted unchanged in the urine within 24 h. The 
total plasma clearance after oral administration is approximately 
11 L/h and elimination half-life is 4 h [18].
Indications and Usage
It is indicated as a part of treatment and prophylaxis in acute 
exacerbations of chronic bronchitis, RRIs such as rhinitis, 
sinusitis, otitis, pharyngitis, and tonsillitis. PDT has also been 
effective in conditions such as pneumonia and RRIs in children 
with Down’s syndrome (DS) [18].
Dosage in Children
For 2–8 years of age: 400 mg orally twice daily for 15–20 days 
along with standard antibiotic therapy. The maintenance dose is 
400 mg orally once daily without antibiotics for 60 days and the 
prophylaxis dose is 400 mg orally once daily for 60 days [18].
Clinical Evidence of PDT in RRIs
To date, numerous studies have proven the efficacy and safety 
of PDT in the prevention and treatment of RRIs in children 
[Tables 1-3]. Niu et al. conducted a meta-analysis of PDT 
randomized controlled trials (RCTs) in pediatric RRTIs to assess 
the effectiveness and safety of PDT in children <14 years. A total 
of 29 RCTs including 4344 pediatric patients were included in this 
meta-analysis. Ten RCTs out of 29 RCTs were from Italy, Russia, 
or Greece and 19 RCTs were published by Chinese groups.
Patients treated with PDT showed a significant reduction in 
the number of RRTIs compared with conventional treatment. 
PDT treatment also resulted in the remarkably reduced need for 
antibiotics, reduction in the duration of cough and fever, and an 
increase in the levels of serum Igs such as IgA, IgG, and IgM. There 
was no increased risk of adverse events (AEs) of any cause with 
the use of PDT. This recent meta-analysis concluded that PDT has 
good efficacy and safety in the treatment of pediatric RRTIs [20].
Acharya et al. conducted a study of PDT in children with 
RRIs. PDT was given in addition to standard of care for a 
period of 2 months (n=25) and follow-up was done for the 
next 3 months. Significant reduction in the mean number of 
ARI episodes (3.84±0.85 at baseline to 0.48±0.51 at follow-up, 
p<0.0001), duration of acute infectious episodes (p<0.0001), 
need of antibiotic courses (p<0.0001), and rates of hospitalization 
(p<0.0001) were observed. PDT was well tolerated [21].
Das et al. conducted a study in 63 children aged 2–10 years 
with RRIs. Participants were allocated to PDT (400 mg twice 
daily for 15 days and once daily for 2 months, n=43) and placebo 
(n=20) groups. All participants were followed up for 6 months. 
PDT resulted in a significantly lower number of recurrences in 
the overall study population as well as in those with existing 
asthma (44.2% in PDT and 25% in placebo groups). No AEs were 
reported in this study [22].
Walavalkar et al. divided 193 children aged 1–12 years, 
with a history of RRIs to PDT and placebo groups. PDT group 
received the drug 400 mg twice a day for 15 days and once a 
day for 30 days, (n=96) and the other group received matching 
placebo (n=97). All participants were followed for 6 months 
after the treatment. Significant improvement in clinical signs and 
symptoms was seen in the PDT group than the placebo group at 
15 days and 45 days of assessment. Furthermore, significantly 
lower relapse rate was seen at 15 days (8.91% vs. 66.66%, p<0.05) 
and at 45 days (1.98% vs. 18.18%, p<0.05) assessments but non-
significantly lower in 6-month follow up period (7% vs. 10%). 
Overall efficacy and safety rating by physicians and patients was 
excellent for PDT as compared to placebo (79.2% vs. 16.2% and 
77.2% vs. 18.2%, respectively) [23].
Namazova-Baranova et al. performed a study in children aged 
3–6 years with RRIs and randomized to PDT (400 mg once a day 
for 30 days, n=78) and control (antibiotic therapy, n=79) groups. 
Incidence of ARIs was significantly reduced at 1 (25.6% vs. 
55.7%), 2 (33.3% vs. 77.2%), and 3 (64.1% vs. 98.7%) months of 
treatment. At the end of 6 month’s treatment, 92.3% and 100.0% 
of patients from the two groups had developed ARI episodes. PDT 
also reduced the severity of ARIs as evidenced by a lesser number 
of moderate episodes (16.6% vs. 44.3%) and milder episodes 
(82.1% vs. 55.7%). IgE levels were decreased by 25.3% and 
53.8% of patients from the two groups, respectively. Furthermore, 
PDT switched the immune response to Th1 type. Levels of IL-8 
were significantly reduced with PDT at 3 months [24].
Licari et al. randomized children aged 3–10 years with RRIs to 
PDT 400 mg once a day for 60 days plus antibiotic and supportive 
treatment (n=45) and control (antibiotic and supportive treatment 
without PDT) (n=44) groups. All participants were followed up 
for 2 months. Significant improvement in upper and lower 
airway symptoms at day 30 and day 60 was seen in children who 
received PDT as compared to the control group. Furthermore, the 
number of children who required other rescue medications was 
significantly lower with PDT. School absenteeism and visits to 
pediatric clinics for RRIs were also reduced in the PDT group. 
There were no significant AEs reported in this study [25].
Del-Rio-Navarro et al. conducted a meta-analysis of 
studies of immunostimulants in children (age <18 years) with 
RRIs. The outcomes assessed were the mean number of ARIs 
and the percentage change in the rate of ARIs. It included 
a total of 35 placebo-controlled trials consisting of 4060 
participants in the meta-analyses. Immunostimulant reduced 
the total numbers of acute respiratory tract infections (ARTIs) 
(mean difference [MD] −1.24; 95% confidence interval [CI] 
−1.54 –−0.94) and the difference in ARTI rates (MD −38.84%; 
95% CI −46.37% –−31.31%) versus placebo. This confirms that 
the use of immunostimulants reduces ARIs incidence rate [26].
Aivazis et al. performed a study in children aged 2.5–12 years 
with RRIs. One group received treatment with PDT (400 mg twice 
daily for 15 days followed by once daily for 20 days, n=15) and 
the other group received broad-spectrum antibiotics without PDT 
(n=32). All participants were followed up for 9 months. Two or 
fewer recurrences were reported in 87.5% of children in the PDT 
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Table 1: Clinical studies of PDT in children with RRIs
Study 
(year)













addition to standard 
of care (n=25)
3 months ↓Number of RRI episodes, duration of 






RCT Children with 
RRIs, 2–10 
years
PDT (n=43) versus 
placebo (n=20), for 
75 day
6 months ↓RRI episodes in all children









placebo (n=97) 15 
day; Maintenance: 
PDT 30 day
6 months Improvement in clinical symptoms









RCT Children with 
RRI, 3–6 years
PDT (n=78) versus 
control (n=79) for 
30 days
6 months ↓Incidence of ARIs at 1, 2 and 3 
month ARI in total 6 month: 92.3% 




RCT Children with 
RRI, 3–10 
years
PDT (n=50) versus 
placebo (n=50) for 
60 days
2 months ↓Number of children with respiratory 





RCT Children with 
RRI, 2.5–12 
years
PDT (n=32) versus 
no PDT (n=18)
9 months ≤2 recurrence: 87.5 versus 33.3%
Clearance time of respiratory 





RCT Children with 
RRI, 3–14 
years
PDT (n=309) versus 
placebo (n=327) for 
60 day
90 days ↓RRI incidence, symptoms school 




Yue and Yu, 
2017 [29]
RCT Children with 
RRI
PDT versus spleen 
aminopeptide (n=86) 
for 3 month
- ↓Duration of symptoms -
Passali 
et al. [30]
RCT Children with 
RRI, 3–14 
years
PDT (n=205) versus 
placebo (n=211) for 
60 day
90 days ↓Duration and frequency of RRIs, 
fever, severity of symptoms, 





RCT Children with 
RRI, 2–8 years
PDT (n=60) versus 
placebo (n=60) for 
75 day
- Normalization of chemotaxis and 








RCT Children with 
RRI, 2–13 
years
PDT (n=52) versus 
placebo (n=49) for 
60 days










PDT (n=177) versus 
placebo (n=118) for 
75 days
90 days ↓Inflammatory episodes, clinical 




*Only statistically significant findings (exceptions mentioned as nonsignificant), RCT: Randomized controlled trial, PDT: Pidotimod, AEs: Adverse events, NR: Not reported, 
RRI: Recurrent respiratory infection, ARIs: Acute respiratory infections
Table 2: Clinical studies of PDT in RRIs in children with DS





DS and RRI, 3–13 years PDT (n=14) versus control 
(n=12) for 90 days
↓Frequency, severity and duration of 
infectious episodes, ↓Mucosal hyperemia, 
nasal secretions and obstructions
Zuccotti and 
Mameli [35]
RCT DS and ARIs, virosomal-
adjuvanted influenza vaccine 
administered in all, 3–10 year
PDT (n=9) versus placebo 
(n=9) for 90 days
Upregulation of genes involved in activation 
of innate immunity and antimicrobial 
activity, increment in flu-specific IgG1/
G3 suggesting activation of complement-
dependent mechanism
*Only statistically significant findings (exceptions mentioned as non-significant), RCT: Randomized controlled trial, PDT: Pidotimod, AEs: Adverse events, NR: Not reported, 
DS: Down’s syndrome, RRI: Recurrent respiratory infection, ARIs: Acute respiratory infections, Ig: Immunoglobulin
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group whereas three or more recurrences seen in 33.3% children 
in the control group in 9 months follow-up period (p<0.0001). 
Mucociliary clearance time of respiratory epithelium decreased 
significantly with PDT (from 37–19.5 min, p<0.001) than the 
control group (from 36.4–31 min, p>0.05) at 6 months follow up. 
This improved functioning ciliary epithelium contributes to 
improved clinical outcomes in RRIs [27].
Careddu conducted a study in 671 children (3–14 years) 
with RRI. PDT (n=329) significantly reduced number of RRI 
episodes (no episodes: 55.3% vs. 34.8%, p<0.01) compared 
to placebo (n=342). Furthermore, PDT significantly reduced 
associated clinical signs and symptoms, school absenteeism, use 
of antibiotics, and other treatments. The study population was 
followed up for 3 months after completion of therapy. During 
the follow-up period too, PDT group reported a significantly 
fewer number of recurrences. Both treatments were well tolerated 
(number of patients with AEs: 22 vs. 15) [28].
Yue and Yu did a comparative study of PDT with spleen 
aminopeptide in 86 children with RRIs for 3 months. PDT 
significantly improved clinical symptoms and decreased its 
duration. Furthermore, the levels of IL-4 and IFN-γ were 
significantly improved with PDT than control [29]. Passali et al. 
conducted a study on 416 children with RRIs. Treatment with 
PDT (n=205) and placebo (n=211) was given for 60 days and then 
followed up for 3 months. The recurrence rate was significantly 
lower in PDT group than placebo (56.1% vs. 68.8%, p=0.014). 
The median time for relapse was greater in PDT than placebo 
(48 vs. 24 days) groups. Similarly, a significant reduction in 
clinical signs and symptoms and use of antibiotics were observed 
with PDT with an excellent safety profile [30].
Caramia et al. conducted RCT in 120 children with RRIs. 
PDT treatment (400 mg twice a day for 15 days [acute phase] 
and once a day for 60 days [maintenance phase], n=60) was 
associated with quicker recovery (10.8 vs. 13 days, 2.2 days, 
p<0.01), shorter duration of antibiotics (7.6 vs. 10 days, p<0.01) 
and hospitalization (6.4 vs. 8.5 days, p<0.01), and clinical signs 
and symptoms as compared to placebo (n=60). Furthermore, 
the normalization of chemotaxis and leukocyte phagocytosis 
index was observed which indicates improved immune response 
by PDT. A significant decrease in relapse rate (39 vs. 60, 35% 
reduction, p<0.05) was observed and it was well tolerated [31].
Similarly, Burgio et al. performed a study of 101 children 
aged 2–13 years with RRI. Treatment given was either PDT 
or placebo for 60 days and followed for 60 more days. PDT 
treatment resulted in a significant reduction in clinical features 
of both lower and upper respiratory infections (p<0.05). During 
follow-up, only 16% and 18% of patients in PDT presented 
with lower and upper respiratory symptoms than 42.5% and 
62.5% of patients in placebo group (p<0.05). Further, the need 
for antibiotics and supportive treatment and medical assistance 
was significantly reduced. PDT was well tolerated in the study. 
Immunological assay with phytohemagglutinin stimulation in 
18 patients has shown that PDT significantly increased cells with 
expression of CD25+ (7 out of 8) than placebo (3 out of 10) (88% 
vs. 30%, p<0.05) [32].
Motta et al. randomized 235 children (3–14 years) with 
recurrent tonsillitis to PDT or placebo group. Treatment was 
given for 75 days and all participants were followed up for the 
next 90 days. Numbers of inflammatory upper airway episodes 
were significantly reduced during treatment as well as follow-up 
period. One, two, three, and four episodes or recurrences were 
seen in 35.7%, 21.4%, 8.9%, and 0.9% patients in PDT group 
and in 20.7%, 24.3%, 17.1%, and 9.9% in placebo group, 
respectively (p<0.001). It was observed that the median time for 
the appearance of the first relapse was higher in PDT than in the 
placebo group (41 vs. 24 days). PDT group reported a significant 
reduction in clinical signs and symptoms, antibiotic usage, and 
school absenteeism with an excellent safety [33].
DS is characterized by alterations in immune functions, which 
makes these children more susceptible to different infections. To 
test this hypothesis, some investigators conducted studies with 
PDT in children with DS suffering from RRIs. La Mantia et al. 
conducted a study in children with DS suffering from RRIs. One 
group received PDT 400 mg once a day for 90 days (n=14) and 
the control group (n=12) did not receive PDT. It significantly 
reduced the frequency of RRIs (2.71 vs. 6.82, p<0.001), severity, 
and duration of infectious episodes. Furthermore, there was a 
significant improvement in mucosal hyperemia, nasal secretions, 
and nasal respiratory obstructions with PDT therapy. There were 
no AEs with the PDT treatment [34].
Another study by Zuccotti and Mameli enrolled DS children 
aged 3–10 years with ARIs to PDT 400 mg once a day for 90 days 
(n=9) or placebo (n=9). The upregulation of genes involved in 
the activation of innate immune responses and in antimicrobial 
activity was observed with PDT treatment. In additional, flu-
specific IgG1 was increased whereas levels of IgG3 were reduced 





Study population Treatment Follow-up Efficacy%*
Esposito 
et al. [36]
RCT Children with CAP, 
3–14 years
PDT+antibiotics (n=10) 
versus antibiotics (n=10) 
for 14 d
7 days ↑DC expressing activation and costimulatory 
molecules, ↑TNF-α and IL-12 secretion, 
↑Release of pro-inflammatory cytokines from 
monocytes, ↑TLR-2 expression in CD14+cells
Hong-Qiu 
et al. [37]
Unclear Children with 
Mycoplasma 
pneumoniae pneumonia
PDT versus general 
therapy (n=35) for 3–5 d
- ↑Number of CD4+ cells, ↑ and CD4+/CD8+ 
ratio
*Only statistically significant findings (exceptions mentioned as nonsignificant). RCT: Randomized controlled trial, PDT: Pidotimod, CAP: Community-acquired pneumonia, 
DC: Dendritic cell, TNF-α: Tumor necrosis factor-alpha, IL: Interleukin, TLR: Toll-like receptor
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after 90 days of treatment with PDT. These results suggest that PDT 
stimulates complement-dependent effects or mechanisms [35].
Esposito et al. randomized 20 children with community-acquired 
pneumonia (CAP) into two groups. One group received antibiotic 
therapy plus PDT (800 mg/d in twice daily) and other group 
received standard antibiotic therapy alone for 14 days. The levels of 
tumor necrosis factor-alpha and/or IL-12 and expression of TLR-2 
were significantly increased in PDT group as compared to controls. 
The study concluded that PDT has immunomodulatory effects in 
children with CAP when administered along with antibiotics [36].
Hong-Qiu et al. conducted a study in 35 children with 
Mycoplasma pneumoniae pneumonia divided into two groups. 
One group received azithromycin only and the other group 
received azithromycin plus PDT for 3–5 days. Nine healthy 
controls were also enrolled for comparisons. Azithromycin group 
had low levels of CD4+ cells and a low ratio of CD4+/CD8+ 
cells than healthy controls. PDT group demonstrated a significant 
increase in the number of CD4+ cells (p<0.05). This study 
concluded that PDT upregulates T-lymphocyte subsets which 
may help in early recovery from M. pneumoniae pneumonia [37].
Recently, Shi et al. conducted one study of PDT in children 
with M. pneumonia. Of 149 children, 79 were treated with PDT 
and azithromycin, and 70 controls were treated with azithromycin 
sequential therapy. After treatment, serum IL-10 and granulocyte 
colony-stimulating factor (G-CSF) levels were significantly lower 
in cases than in controls. Furthermore, a significant positive 
correlation was observed between IL-10 and G-CSF levels before 
and after treatment in PDT group (p<0.05), and a significant positive 
correlation between expression levels of IL-10 and G-CSF before 
and after treatment in the control group (p<0.05). Improved curative 
effect and reduced occurrence of adverse reactions were observed in 
the observation group as compared to the control group [38].
Place in Therapy
Current clinical evidence of PDT in the treatment and prevention 
of RRIs in children is very robust and it suggests that PDT is an 
effective and safe treatment strategy in the management of RRIs. 
Compliance with recommended therapy of PDT for a period of 
2 months is essential for the prevention of further episodes of 
RRIs. It not only reduces the RRIs but it also reduces the duration 
of cough and fever and also the need for antibiotic therapy. PDT 
therapy results in faster recovery and reduces school absenteeism. 
Reduced antibiotic usage can further help to prevent the problem of 
antibiotic resistance in RRI management. PDT improves immune 
function in children with immune dysfunction or physiological 
immaturity of the immune system and reduces RRIs. Thus, PDT 
can be a very good treatment option along with the standard of 
care in RRI patients.
CONCLUSION
PDT acts on both innate and adaptive immune systems and 
improves the overall functioning of the immune system. It is 
safe and effective in the treatment and prevention of RRIs in 
children. Available clinical evidence strongly supports its use in 
the management of RRIs in children.
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